Randomized Double-blind Placebo-Controlled Trial in the Treatment of Alopecia Areata With 0.25% Desoximetasone Cream

Charuwichitratana, Somyot; Wattanakrai, Penpun; Tanrattanakorn, Somsak

doi:10.1001/archderm.136.10.1276

Cited by 61 publications

(45 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A potent topical steroid (for example, clobetasol) delivered in a lotion, foam, or shampoo formulation can be used for limited patchy alopecia areata and may speed recovery of hair growth in mild degrees of alopecia areata 138–140 . Treatment should be continued for at least three months but should be stopped after 6 months if there is no response.…”

Section: Mechanisms/pathophysiologymentioning

confidence: 99%

Alopecia areata

Pratt

King

Messenger

et al. 2017

Nat Rev Dis Primers

576

528

View full text Add to dashboard Cite

Alopecia areata is an autoimmune disorder characterized by transient, non-scarring hair loss and preservation of the hair follicle. Hair loss can take many forms ranging from loss in well-defined patches to diffuse or total hair loss, which can affect all hair bearing sites. Patchy alopecia affecting the scalp is the most common type. Alopecia areata affects nearly 2% of the general population at some point during their lifetime. Skin biopsies of alopecia areata affected skin show a lymphocytic infiltrate in and around the bulb or the lower part of the hair follicle in anagen (hair growth) phase. A breakdown of immune privilege of the hair follicle is thought to be an important driver of alopecia areata. Genetic studies in patients and mouse models showed that alopecia areata is a complex, polygenic disease. Several genetic susceptibility loci were identified associated with signaling pathways that are important to hair follicle cycling and development. Alopecia areata is usually diagnosed based on clinical manifestations, but dermoscopy and histopathology can be helpful. Alopecia areata is difficult to manage medically, but recent advances in understanding the molecular mechanisms have revealed new treatments and the possibility of remission in the near future.

show abstract

Section: Mechanisms/pathophysiologymentioning

confidence: 99%

Alopecia areata

Pratt

King

Messenger

et al. 2017

Nat Rev Dis Primers

576

528

View full text Add to dashboard Cite

show abstract

“…Oft werden topische Kortikosteroide eingesetzt, wenngleich deren Wirksamkeit in nur 2 kontrollierten Studien aus den 60er-Jahren gezeigt werden konnte. Neuere Studien können die Ergebnisse nicht bestätigen [5]. Eine mögliche Ursache der mangelnden Wirksamkeit könnte eine unzureichende Penetration der topisch applizierten Kortikosteroide bis zu den im subkutanen Fettgewebe liegenden Haarbulbi sein.…”

Section: Alopecia Areataunclassified

Differenzialdiagnose des atopischen Ekzems in der Kindheit

et al. 2007

View full text Add to dashboard Cite

Atopic eczema (AE) is a chronic inflammatory skin disease which affects 10 to 20% of children and 1 to 3% of adults. AE is usually diagnosed based on standard criteria such as those of Hanifin and Rajka, whereby the age-related variation must be considered. There are numerous other diseases which go along with AE or show a very similar clinical picture and represent important differential diagnostic considerations including parasitic diseases, immunodeficiency, nutritional diseases, certain neoplastic disorders and various corneal abnormalities. Additionally, it is important to consider diseases which can occur in association with AE, such as keratosis pilaris, alopecia areata or sweat disturbances.

show abstract

“…In a double-blind placebo-controlled study, rate of complete hair growth was not statistically significant with 12 weeks use of 0.25% desoximetasone cream, twice daily, when compared with placebo [44]. A half-head comparison trial performed with 0.05% clobetasol propionate foam and vehicle found at least 50% regrowth of hair after 12 weeks of clobetasol treatment.…”

Section: Topical Corticosteroidsmentioning

confidence: 92%

Alopecia Areata

Engın¹,

Oba²,

Tüzün³

2017

Hair and Scalp Disorders

View full text Add to dashboard Cite

Alopecia areata is an organ-specific autoimmune disease targeting hair follicles. It causes nonscarring hair loss. The prevalence rate of the disease is approximately 1 in 1000 people worldwide. The condition is most commonly seen as circular areas of hair loss, but it may sometimes be as extensive as to involve the whole scalp or whole body. The complex pathophysiology of alopecia areata involves an autoimmune basis. Association of alopecia areata with other autoimmune diseases, such as thyroiditis and vitiligo, and the good response of patients to immunosuppressive treatment support an autoimmune etiology. Although some poor prognostic signs are defined, the course of the disease is unpredictable and the response to treatment can be variable. To date, there are neither preventive nor curative measures to deal with the condition. First-line therapy for patchy disease is topical and intralesional steroids, whereas extensive disease is conventionally managed with immunotherapy. New treatment agents, such as excimer laser, low-dose recombinant interleukin 2, Janus kinase inhibitors, and simvastatin/ezetimibe, are promising.

show abstract

Randomized Double-blind Placebo-Controlled Trial in the Treatment of Alopecia Areata With 0.25% Desoximetasone Cream

Cited by 61 publications

References 5 publications

Alopecia areata

Alopecia areata

Differenzialdiagnose des atopischen Ekzems in der Kindheit

Alopecia Areata

Contact Info

Product

Resources

About